leisure time -WSS

leisure time

author：hotspot 2025-10-01 23:57:25 - browse：22974

Susan Galbraith of AstraZeneca gestures while speaking – pharma coverage from STAT — Susan Galbraith, AstraZeneca’s head of cancer research and development, speaks at a STAT event in 2023. Marie Miller for STAT

CHICAGO — AstraZeneca’s head of cancer research and development, Susan Galbraith, is British, and prone to a particularly British style of understatement. She doesn’t boast loudly. But she did come to this year’s annual meeting of the American Society of Clinical Oncology wearing a small lapel pin with the numeral 6 and the “AZ” corporate logo.

That pin represents the number of years in a row that the London-based drug giant has had a presentation in the ASCO plenary, the conference’s biggest showcase for new data. This year, the company has two.

Scientific credibility is great, of course. But AstraZeneca’s shareholders want something else: return on investment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： The stock market has soared this year, but will it last? Experts weigh in

WSS

Extensive review finds private equity owners jack up cost of care

How I ended up pumping milk in a bathroom stall at JPM 2024

How I ended up pumping milk in a bathroom stall at JPM 2024

When a patient nears the end, a feared therapy can comfort

5 dead in mass shooting on Caribbean island of St. Vincent: Police

After a decade, new Gardasil ad campaign gets it (mostly) right

knowledge

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Biotech reporter’s notebook: A sunnier mood at JPM 2024

State Dept. review finds Biden bears some blame for Afghanistan failures

Are infertility treatments 'essential' during the Covid

What does generative AI mean for health care? We asked experts

Idaho abortion case may prompt more restrictions in other states

Moonlake's readout produced a cash windfall. Risks remain

Thousands of UK hospital doctors walk out in the latest pay dispute, crippling health services

The high cost of giving birth even with insurance

Hormonal contraceptives don’t actually treat endometriosis

leisure time

As JPM 2024 winds down, some health tech firms project optimism

Doulas covered by Medicaid under New York's new plan

Doulas covered by Medicaid under New York's new plan

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

GSK to buy asthma

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

explore

hotspot

explore

focus